TheEdgeResearch
Home / Stocks / CMOPF

Cosmo Pharmaceuticals N.V. (CMOPF)

OTC Healthcare Medical - Pharmaceuticals
$76.80 ▲ +1.96%
Market Cap
$1.32B
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Beta
1.49
52-Wk Range
73-169.9
CEO
Giovanni di Napoli
Country
IE
Currency
USD

Cosmo Pharmaceuticals N.V. operates in the Medical - Pharmaceuticals industry of the Healthcare sector, headquartered in Dublin, DU, IE. The stock last traded at $76.80, up 1.96% on the session, giving a market capitalisation of $1.32B. On trailing twelve-month figures it carries a trailing P/E of -170.94, a net margin of -6.2%. Its beta of 1.49 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-170.94
Price / Sales
10.87
Price / Book
1.95
EV / EBITDA
-1711.92
Gross margin
45.5%
Operating margin
-13.4%
Net margin
-6.2%
Return on equity
Debt / equity
0.01
Current ratio
10.66
Dividend yield
3.2%
Payout ratio
-693.2%
Company profile
Exchange
Other OTC
Employees
324
IPO date
2017-07-31
Headquarters
Dublin, DU, IE
About Cosmo Pharmaceuticals N.V.

Cosmo Pharmaceuticals N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delivers budesonide directly to the lumen of the colon; Eleview, an injectable composition to allow endoscopists with excision of gastrointestinal lesions; Lumeblue, a diagnostic drug for the visualisation of colorectal lesions during colonoscopies; Aemcolo/Rifamycin, a pharmaceutical drug product in form of tablets that is approved for the treatment of travelers' diarrhoea; and Clascoterone, which is in phase-3 clinical trial for the treatment of male pattern hair loss. It is also developing novel UC treatment, which is in phase-2 clinical trial for the treatment of distal inflammatory bowel disease/distal ulcerative colitis/proctitis; BAD Treatment (CB-01-33), which is in phase-2 clinical trial for the treatment of colesevelam formulation/bile acid diarrhea; and CB-03-10, which is in phase-1 clinical trial for the treatment of oncology solid tumors, as well as provides Cosmo's AI technology, a GI Genius intelligent endoscopy system. The company was founded in 1997 and is headquartered in Dublin, Ireland.

Comparable companies

Cosmo Pharmaceuticals N.V. is most often compared with the following Healthcare names:

CHIZFEVOTFGNTLFKSPHFLJUIFNPPNYRAFLFSWGHFTCNNFTWAPF
More research on CMOPF
CMOPF technical analysis CMOPF TheEdge Score Compare against peers
Open full interactive analysis & DCF →